Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-06-05
2000-08-01
Campell, Bruce R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 44, 514 1, 4353201, A01N 4304, A01N 6100, C12N 1500
Patent
active
060967188
ABSTRACT:
Replication defective adenoviral vectors serve as vehicles for genes encoding products that kill cells in which the genes are transferred and activated. The novel vectors include tissue specific promoters, and are successful in targeting mammalian cancer cells, in particular human breast cancer cells, and causing tumors to regress.
REFERENCES:
patent: 5612185 (1997-03-01), Uhr et al.
patent: 5631236 (1997-05-01), Woo et al.
Jolly D., Cancer Gene Therapy, vol. 1 (1), p. 51-64, 1994.
Stinnakre et al., FEBS, vol. 284 (1), p. 19-22, Jun. 1991.
Hall et al., Biochem. J., vol. 242, p. 735-742, 1987.
Shani et al., Transgenic Research, vol. 1, p. 195-208, 1992.
Alam, J., et al.(1990) "Reporter Genes: Application to the Study of Mammalian Gene Transcription," Anal. Biochem., 188:245-254.
Ali, S., et al., (1990) "Characterisation of the Alleles Encoding Ovine .beta.-Lctoglobulins A and B," Gene, 91:201-207.
Alvarez, R., et al., (1997) "A Phase I Study of Recombinant Adenovirus Vector-Mediated Intraperitoneal Delivery of Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene and Intravenous Ganciclovir for Previously Treated Ovarian and Extraovarian Cancer Patients," Human Gene Therapy, 8:597-613.
Chen, L., et al., (1995) "Breast Cancer Selective Gene Expression and Therapy Mediated by Recombinant Adenoviruses Containing the DF3/MUC1 Promoter," J. Clin. Invest., 96:2775-2782.
Chen, S.H., et al., (1996) "Combination Suicide and Cytokine Gene Therapy for Hepatic Metastases of Colon Carcinoma: Sustained Antitumor Immunity Prolongs Animal Survival," Cancer Research, 56:3758-3762.
Gould, M.N., (1995) "Rodent Models for the Study of Etiology, Prevention and Treatment of Breast Cancer," Cancer Biology, 6:147-152.
Graham, F.L., et al., (1977) "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," J. Gen. Virol., 36:59-72.
Halbert, D.N., et al., (1985) "Adenovirus Early Region 4 Encodes Functions Required for Efficient DNA Replication, Late Gene Expression, and Host Cell Shutoff," J. Virol., 56:250-257.
Hall, L., et al., (1987) "Organization and Sequence of the Human .alpha.-Lactalbumin Gene," Biochem J., 242:735-742.
Harris, S., et al., (1991) "Developmental Regulation of the Sheep .beta.-Lactogloblin Gene in the Mammary Gland of Transgenic Mice," Dev. Genet., 12:299-307.
Jones, N., et al., (1979) "Isolation of Adenovirus Type 5 Host Range Deletion Mutants Defective for Transformation of Rat Embryo Cells," Cell, 17:683-689.
Kanai, F., et al., (1997) "In Vivo Gene Therapy for .alpha.-Fetoprotein-Producing Hepatocellular Carcinoma by Adenovirus-Mediated Transfer of Cytosine Deaminase Gene.sup.1," Cancer Research, 57:461-465.
Katayose, D., et al., (1995) "Cytotoxic Effects of Adenovirus-Mediated Wild-Type p53 Protein Expression in Normal and Tumor Mammary Epithelial Cells," Clin. Canc. Res., 1:889-897.
Kwong, Y.L., et al., (1996) "Adenoviral-Mediated Suicide Gene Therapy for Hepatic Metastases of Breast Cancer," Cancer Gene Therapy, 3(5):339-344.
Leimeg, T., et al., (1996) "High-Efficiency Transduction of Freshly Isolated Human Tumor Cells Using Adenoviral Interleukin-2 Vectors," Human Gene Therapy, 7:1233-1239.
Manome, Y., et al., (1994) "Enhancer Sequences of the DF3 Gene Regulate Expression of the Herpes Simplex Virus Thymidine Kinase Gene and Confer Sensitivity of Human Breast Cancer Cells to Ganciclovir," Cancer Res., 54:5408-5413.
Marcel, T., et al., (1997) "The TMC Worldwide Gene Therapy Enrollment Report, End 1996," Human Gene Therapy, 8:775-800.
Marini III, F.C., et al., (1995) "Assessment of Bystander Effect Potency Produced by Intratumoral Implantation of HSVtk-Expressing Cells Using Surrogate Marker Secretion to Monitor Tumor Growth Kinetics," Gene Therapy, 2:655-659.
Ohwada, A., et al., (1996) "Regional Delivery of an Adenovirus Vector Containing the Escherichia coli Cytosine Deaminase Gene to Provide Local Activation of 5-Fluorocytosine to Suppress the Growth of Colon Carcinoma Metastatic to Liver," Human Gene Therapy, 7:1567-1576.
Ranheim, S., et al., (1993) "Characterization of Mutants within the Gene for the Adenovirus E3 14.7-Kilodalton Protein Which Prevents Cytolysis by Tumor Necrosis Factor," Journal of Virology, 67(4):2159-2167.
Saito, I., et al., (1985) "Construction of Nondefective Adenovirus Type 5 Bearing a 2.8-Kilobase Hepatitos B Virus DNA Near the Right End of Its Genome," Journal of Virology, 54(3):711-719.
Swaminathan, S., et al., (1996) "Transactivation of Adenovirus E2-early Promoter by E1A and E4 6/7 in the Context of Viral Chromosome," J. Mol. Biol., 258:736-746.
Yee, D., et al., (1996) "Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase in an Ascites Model of Human Breast Cancer," Human Gene Therapy, 7:1251-1257.
Jolly D. (Cancer Gene Therapy, vol. 1, No. 1, 1994, p51-64).
Stinnakre et al. FEBS (Fed Eur Biochem Soc) LETT 284 (1). 1991. 19-22).
Myal et al. (Mol Cell Endocrinol 80 (1-3). 1991. 165-176).
Mastrangelo et al. (Seminars in Oncology, vol. 23, 1996, p4-21).
Anderson Leonard
Thimmapaya Bayar
Weitzman Sigmund
Campell Bruce R.
Chen Shin-Lin
Gene Targeting Corp.
Martin Alice O.
LandOfFree
Tissue specific adenovirus vectors for breast cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue specific adenovirus vectors for breast cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue specific adenovirus vectors for breast cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-663955